Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 2/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 2/20 | 1.00 |
| ▸ | CILK1 | Q9UPZ9 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | DDX42 | Q86XP3 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 0.98 |
| ▸ | CDK2 | P24941 | 12/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL290347 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663220 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL29505152 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL6119675 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663219 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL23683025 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL17348307 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL665749 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL31702788 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL291157 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3325504-B1 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4706773-A2 | HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| EP-3344996-B1 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062712-A1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-20260042812-A1 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | NOVARTIS AG (CH) | 2026-02-12 | — | — | US | disclosed |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220152150-A1 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220145326-A1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3280729-B1 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL | NOVARTIS AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3967709-A1 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | Novartis AG (CH) | 2022-03-16 | — | — | EP | disclosed |
| US-20220072166-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2022-03-10 | — | — | US | disclosed |
| WO-2022033492-A1 | QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2 | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078341-A1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | LY96, CD74, EWSR1 | CDK4 3737/4885CDK1 3485/4885CDK9 3068/4885 |
| US-20220162200-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PKM, PDK2 | CDK4 239/4885CDK1 200/4885CDK9 454/4885 |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | CDK4 1275/4885CDK1 800/4885CDK9 907/4885 |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | CD2, CD22, KLRK1 | CDK4 2371/4885CDK1 4309/4885CDK9 1959/4885 |
| US-20220072166-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | IL15RA, IL15, SSTR5 | CDK4 2228/4885CDK1 2406/4885CDK9 2998/4885 |
| US-20260062712-A1 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | IGF2BP3, NUDT21, IGF2BP1 | CDK4 2580/4885CDK1 2030/4885CDK9 3425/4885 |
| US-20260042812-A1 | CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | CD22, CD2, CD2BP2 | CDK4 2074/4885CDK1 2464/4885CDK9 2080/4885 |
| US-20220152150-A1 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | CD47, CD4, HAVCR2 | CDK4 4508/4885CDK1 4062/4885CDK9 3968/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | CDK4 26/4885CDK1 114/4885CDK9 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.